Cargando…
Regulation of efferocytosis as a novel cancer therapy
Efferocytosis is a physiologic phagocytic clearance of apoptotic cells, which modulates inflammatory responses and the immune environment and subsequently facilitates immune escape of cancer cells, thus promoting tumor development and progression. Efferocytosis is an equilibrium formed by perfect co...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199874/ https://www.ncbi.nlm.nih.gov/pubmed/32370748 http://dx.doi.org/10.1186/s12964-020-00542-9 |
_version_ | 1783529229760069632 |
---|---|
author | Zhou, Yunxiang Yao, Yihan Deng, Yongchuan Shao, Anwen |
author_facet | Zhou, Yunxiang Yao, Yihan Deng, Yongchuan Shao, Anwen |
author_sort | Zhou, Yunxiang |
collection | PubMed |
description | Efferocytosis is a physiologic phagocytic clearance of apoptotic cells, which modulates inflammatory responses and the immune environment and subsequently facilitates immune escape of cancer cells, thus promoting tumor development and progression. Efferocytosis is an equilibrium formed by perfect coordination among “find-me”, “eat-me” and “don’t-eat-me” signals. These signaling pathways not only affect the proliferation, invasion, metastasis, and angiogenesis of tumor cells but also regulate adaptive responses and drug resistance to antitumor therapies. Therefore, efferocytosis-related molecules and pathways are potential targets for antitumor therapy. Besides, supplementing conventional chemotherapy, radiotherapy and other immunotherapies with efferocytosis-targeted therapy could enhance the therapeutic efficacy, reduce off-target toxicity, and promote patient outcome. |
format | Online Article Text |
id | pubmed-7199874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71998742020-05-06 Regulation of efferocytosis as a novel cancer therapy Zhou, Yunxiang Yao, Yihan Deng, Yongchuan Shao, Anwen Cell Commun Signal Review Efferocytosis is a physiologic phagocytic clearance of apoptotic cells, which modulates inflammatory responses and the immune environment and subsequently facilitates immune escape of cancer cells, thus promoting tumor development and progression. Efferocytosis is an equilibrium formed by perfect coordination among “find-me”, “eat-me” and “don’t-eat-me” signals. These signaling pathways not only affect the proliferation, invasion, metastasis, and angiogenesis of tumor cells but also regulate adaptive responses and drug resistance to antitumor therapies. Therefore, efferocytosis-related molecules and pathways are potential targets for antitumor therapy. Besides, supplementing conventional chemotherapy, radiotherapy and other immunotherapies with efferocytosis-targeted therapy could enhance the therapeutic efficacy, reduce off-target toxicity, and promote patient outcome. BioMed Central 2020-05-05 /pmc/articles/PMC7199874/ /pubmed/32370748 http://dx.doi.org/10.1186/s12964-020-00542-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Zhou, Yunxiang Yao, Yihan Deng, Yongchuan Shao, Anwen Regulation of efferocytosis as a novel cancer therapy |
title | Regulation of efferocytosis as a novel cancer therapy |
title_full | Regulation of efferocytosis as a novel cancer therapy |
title_fullStr | Regulation of efferocytosis as a novel cancer therapy |
title_full_unstemmed | Regulation of efferocytosis as a novel cancer therapy |
title_short | Regulation of efferocytosis as a novel cancer therapy |
title_sort | regulation of efferocytosis as a novel cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199874/ https://www.ncbi.nlm.nih.gov/pubmed/32370748 http://dx.doi.org/10.1186/s12964-020-00542-9 |
work_keys_str_mv | AT zhouyunxiang regulationofefferocytosisasanovelcancertherapy AT yaoyihan regulationofefferocytosisasanovelcancertherapy AT dengyongchuan regulationofefferocytosisasanovelcancertherapy AT shaoanwen regulationofefferocytosisasanovelcancertherapy |